<DOC>
	<DOCNO>NCT00037882</DOCNO>
	<brief_summary>The purpose study determine PEG-Intron well tolerate efficacious standard interferon ( Roferon , Intron ) patient Philadelphia-positive Chronic Myelogenous Leukemia . These patient previously receive standard interferon therapy intolerant , resistant , relapse disease .</brief_summary>
	<brief_title>PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron</brief_title>
	<detailed_description>It show patient experience complete hematologic least partial cytogenetic response interferon improve survival time . In addition , evidence exists even patient demonstrate cytogenetic response interferon treatment still benefit treatment , term survival , compare patient treat interferon . This indicate patient well able tolerate interferon , may improve survival even without cytogenetic response . Preliminary study suggest PEG-Intron convenient patient ( administered weekly rather daily ) , well tolerate interferon , produce hematologic remission interferon-a resistant patient . Phase II study need ascertain overall hematologic cytogenetic response rate PEG-Intron patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Chronic phase CML , document presence Philadelphia chromosome bcr/abl rearrangement time diagnosis , confirm either cytogenetics PCR . WBC &gt; /= 3000/ul &lt; /=100,000/ul . Patients must receive prior interferon therapy &amp; proven primary refractory disease , secondary resistance intolerance interferona Patient must ECOG status 0 , 1 , 2 Labs : SGOT/SGPT &lt; 2xULN ; serum bilirubin &lt; 2xULN ; serum creatinine &lt; 2.0mg/dl Recovered effect major surgery Life expectancy &gt; 12 wks . Signed informed consent . Women childbearing potential must negative serum pregnancy test within 72 hrs prior administration PEGIntron &amp; use effective contraception study . NO accelerate Phase CML patient peripheral blood : blast &gt; /=15 % , basophils &gt; /=20 % , blasts+promyelocytes &gt; /=30 % , platelet &lt; 100,000/ul ( unrelated therapy ) . Blastic phase CML : &gt; /=30 % peripheral blood/bone marrow . NO patient know hypersensitivity interferona . NO severe cardiovascular disease , i.e . arrhythmias require chronic treatment congestive heart failure ( NYHA classification III/IV ) . NO history neuropsychiatric disorder require hospitalization . NO patient require therapy refractory thyroid dysfunction NO patient uncontrolled diabetes mellitus . NO patient treatment 2nd malignancy past 5 yr , except localize basal cell/squamous cell carcinoma skin cervical carcinoma situ . NO pregnant lactate patient . NO patient know actively use alcohol drug NO patient receive experimental therapy within 30 day enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Interferon alpha</keyword>
	<keyword>Roferon</keyword>
	<keyword>Intron</keyword>
	<keyword>Chronic Myelogenous Leukemia-Philadelphia positive</keyword>
</DOC>